In recent years, apple cider vinegar has transcended the kitchen shelf to become a darling of wellness marketing, particularly in India, where influencers, diet fads, and television adverts endorse it as a natural, accessible route to weight loss. From celebrity endorsements to Instagram reels touting morning detox shots, a tablespoon of Apple cider vinegar can melt fat.
Among the research claims lending legitimacy to this narrative was a 2024 small clinical trial published in BMJ Nutrition, Prevention & Health, which asserted that daily consumption of diluted ACV could significantly reduce body weight and BMI in overweight individuals, claims that made headlines globally and have been cited repeatedly in media and health-lifestyle blogs.
But on 24 September 2025, BMJ announced that it had retracted that study. The decision followed a rigorous review by independent statisticians, which found that the results could not be replicated, that there were implausible statistical values, irregularities in raw datasets, insufficient reporting of methodology, and a lack of prior trial registration.
The retraction is a sharp reminder that even health studies that gain popular traction may conceal critical weaknesses, and that consumers should view sensational weight-loss claims with caution. The retracted trial, authored by Rony Abou-Khalil and colleagues, was conducted on 120 participants aged 12 to 25 years who were classified as overweight or obese. Participants were randomised into groups receiving different doses of ACV diluted in water, and the researchers claimed weight loss of 6-8 kg over 12 weeks, along with reductions in BMI (2.7 to 3.0 points) and improvements in metabolic parameters.
The magnitude of weight loss was exceptional: some critics pointed out that if the results were valid, ACV would rival modern pharmacological agents like GLP-1 agonists, an assertion viewed as biologically implausible. Concerns were raised soon after publication. Critics flagged that the trial had no prospective registration, violating common norms for clinical trials and editorial policy.
Questions also surfaced about how statistical analyses were carried out, and about the implausible uniformity of participant characteristics (e.g., extremely similar age and BMI distributions across groups) that seemed unlikely in a real randomised sample.
In response, BMJ’s content integrity team engaged independent statisticians to attempt replication and to check the authenticity of raw data. Their findings were critical: they could not replicate the published results, found multiple analytical errors, noted irregularities in the data sets, and judged that the data from participants warranted further external scrutiny.
While the retracted trial had been a high-visibility piece of evidence often cited in media and wellness content, it was by no means the only study. A body of research, mostly small, short-term trials, has explored ACV’s effects on weight, BMI, waist circumference, glycaemic control, lipid parameters, and appetite.
A 2025 meta-analysis published in Nutrients pooled 10 randomised controlled trials and reported modest yet statistically significant reductions in body weight, BMI, and waist circumference, especially at a dose of 30 mL/day over 12 weeks. However, that same analysis noted high heterogeneity, variable study quality, and reliance on short durations, and in sensitivity analyses excluding high-bias studies, the waist circumference benefit lost significance.
Other studies suggest ACV may help with glycaemic control for diabetes: a meta-analysis of seven trials showed reductions in fasting blood sugar and HbA1c, though effects on insulin resistance (HOMA-IR) were inconsistent. But metabolic effects do not necessarily translate into substantial or sustained weight loss, particularly in free-living humans over longer periods.
In India, ACV products are increasingly advertised with “weight loss”, “slimming,” “detox,” or “fat-melting” slogans. The retraction should prompt regulatory scrutiny (by bodies like FSSAI, ASCI) to ensure that health claims are evidence-based, and that exaggerated or misleading claims are regulated with ample warnings. Many users may self-administer ACV based on social media hype or celebrity endorsements.
The retraction highlights the need for public education: one study, however sensational, is not proof. ACV should not replace a balanced diet, calorie control, exercise, and medical oversight. Even if ACV has modest benefits, its high acidity poses risks: erosion of tooth enamel, throat irritation, gastrointestinal discomfort, potential hypokalaemia, and interactions with medications (e.g. diuretics, insulin). Any use must be diluted, cautious, and ideally guided by medical advice.
